148 related articles for article (PubMed ID: 34895802)
1. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system.
Yang Z; Yu M; Mei M; Chen C; Lv Y; Xiang L; Li R
Nutr Metab Cardiovasc Dis; 2022 Feb; 32(2):504-510. PubMed ID: 34895802
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Fadini GP; Bonora BM; Avogaro A
Diabetologia; 2017 Aug; 60(8):1385-1389. PubMed ID: 28500396
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.
Yang Z; Lv Y; Yu M; Mei M; Xiang L; Zhao S; Li R
Front Pharmacol; 2022; 13():925377. PubMed ID: 36386208
[No Abstract] [Full Text] [Related]
4. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
5. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
7. Asparaginase-related diabetic ketoacidosis: Analysis of the FDA Adverse Event Reporting System (FAERS) data and literature review.
Li D; Gou J; Dong J; Dong Y; Xi X; Chen C; Du Q; Liu S
J Clin Pharm Ther; 2022 Dec; 47(12):2176-2181. PubMed ID: 36411584
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.
Fadini GP; Sarangdhar M; Avogaro A
BMJ Open Diabetes Res Care; 2018; 6(1):e000475. PubMed ID: 29449951
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
[TBL] [Abstract][Full Text] [Related]
10. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
11. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
Chen C; Zhou R; Fu F; Xiao J
Eur Psychiatry; 2023 Nov; 66(1):e99. PubMed ID: 38031404
[TBL] [Abstract][Full Text] [Related]
12. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
13. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
14. Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.
Dauner DG; Farley JF
Expert Opin Drug Saf; 2021 Apr; 20(4):475-480. PubMed ID: 33554677
[No Abstract] [Full Text] [Related]
15. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.
Zhao Z; Tang Y; Hu Y; Zhu H; Chen X; Zhao B
Ann Transl Med; 2021 Sep; 9(18):1482. PubMed ID: 34734034
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Patorno E; Pawar A; Bessette LG; Kim DH; Dave C; Glynn RJ; Munshi MN; Schneeweiss S; Wexler DJ; Kim SC
Diabetes Care; 2021 Mar; 44(3):826-835. PubMed ID: 33495295
[TBL] [Abstract][Full Text] [Related]
18. Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.
Sugawara N; Yasui-Furukori N; Shimoda K
J Psychosom Res; 2023 Dec; 175():111533. PubMed ID: 37866219
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Bonora BM; Raschi E; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
[TBL] [Abstract][Full Text] [Related]
20. Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.
Edwards K; Uruska A; Duda-Sobczak A; Zozulinska-Ziolkiewicz D; Lingvay I
Ther Adv Endocrinol Metab; 2023; 14():20420188231180987. PubMed ID: 37440840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
